Therapy with monoclonal anti-FGF-23 antibodies in CKD stages 2 to 4 probably would result in hyperphosphatemia because of reduced urinary phosphate excretion and enhanced 1,25(OH)2D3-dependent intestinal phosphate absorption. Here, FGF23 is linked to chronic kidney disease.